The competitive market for antiplatelets and thrombolytics: can a new entrant succeed?
The current lack of available antiplatelet and thrombolytic agents, the limitations of existing products, the possibility of value-pricing, and the sheer number of potential candidates for therapy all combine to produce a market with tremendous potential. Given these very significant incentives, it is no wonder that so many pharmaceutical companies have chosen to pursue research in the antithrombotic field.
L Y
LY
Shepard
D004345:Drug Industry / Q000191:economics; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors